Last 12 months
Inside the activity.
0 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2013 Filed Jan 30, 2013 21:16 UTC |
GLIMCHER LAURIE H M.D.Director
|
Exercise / conversionOption (right to buy) · Derivative | 3,500 | $0.00 Strike: $25.51 | $0.00 |
DisclosureSEC source: 0001225208-13-002480 · doc4.xml · derivative · entry 9 GLIMCHER LAURIE H M.D. · CIK 0001255051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 3,500 shares Expires 2013-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was May 6, 2003. Read SEC document |
| January 30, 2013 Filed Jan 30, 2013 21:16 UTC |
GLIMCHER LAURIE H M.D.Director
|
Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $25.70 | $0.00 |
DisclosureSEC source: 0001225208-13-002480 · doc4.xml · derivative · entry 8 GLIMCHER LAURIE H M.D. · CIK 0001255051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 2,500 shares Expires 2014-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was May 4, 2004. Read SEC document |
| January 30, 2013 Filed Jan 30, 2013 21:16 UTC |
GLIMCHER LAURIE H M.D.Director
|
Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $26.25 | $0.00 |
DisclosureSEC source: 0001225208-13-002480 · doc4.xml · derivative · entry 7 GLIMCHER LAURIE H M.D. · CIK 0001255051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 2,500 shares Expires 2015-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was May 3, 2005. Read SEC document |
| January 30, 2013 Filed Jan 30, 2013 21:16 UTC |
GLIMCHER LAURIE H M.D.Director
|
Exercise / conversionOption (right to buy) · Derivative | 2,500 | $0.00 Strike: $24.96 | $0.00 |
DisclosureSEC source: 0001225208-13-002480 · doc4.xml · derivative · entry 6 GLIMCHER LAURIE H M.D. · CIK 0001255051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 2,500 shares Expires 2016-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was May 2, 2006. Read SEC document |
| January 30, 2013 Filed Jan 30, 2013 21:16 UTC |
GLIMCHER LAURIE H M.D.Director
|
SaleCommon Stock, $0.10 par value | 11,000 | $36.40 | $400,400.00 |
DisclosureSEC source: 0001225208-13-002480 · doc4.xml · nonDerivative · entry 5 GLIMCHER LAURIE H M.D. · CIK 0001255051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 30, 2013 Filed Jan 30, 2013 21:16 UTC |
GLIMCHER LAURIE H M.D.Director
|
Exercise / conversionCommon Stock, $0.10 par value | 2,500 | $24.96 | $62,400.00 |
DisclosureSEC source: 0001225208-13-002480 · doc4.xml · nonDerivative · entry 4 GLIMCHER LAURIE H M.D. · CIK 0001255051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2013 Filed Jan 30, 2013 21:16 UTC |
GLIMCHER LAURIE H M.D.Director
|
Exercise / conversionCommon Stock, $0.10 par value | 2,500 | $25.70 | $64,250.00 |
DisclosureSEC source: 0001225208-13-002480 · doc4.xml · nonDerivative · entry 3 GLIMCHER LAURIE H M.D. · CIK 0001255051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2013 Filed Jan 30, 2013 21:16 UTC |
GLIMCHER LAURIE H M.D.Director
|
Exercise / conversionCommon Stock, $0.10 par value | 2,500 | $26.25 | $65,625.00 |
DisclosureSEC source: 0001225208-13-002480 · doc4.xml · nonDerivative · entry 2 GLIMCHER LAURIE H M.D. · CIK 0001255051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2013 Filed Jan 30, 2013 21:16 UTC |
GLIMCHER LAURIE H M.D.Director
|
Exercise / conversionCommon Stock, $0.10 par value | 3,500 | $25.51 | $89,285.00 |
DisclosureSEC source: 0001225208-13-002480 · doc4.xml · nonDerivative · entry 1 GLIMCHER LAURIE H M.D. · CIK 0001255051 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2013 Filed Jan 30, 2013 21:06 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $36.53 | $365,300.00 |
DisclosureSEC source: 0001225208-13-002478 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.25 to $36.64, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 28, 2013 Filed Jan 28, 2013 21:32 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionOption (right to buy) · Derivative | 22,500 | $0.00 Strike: $28.67 | $0.00 |
DisclosureSEC source: 0001225208-13-002186 · doc4.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 22,500 shares Expires 2014-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 2, 2004. Read SEC document |
| January 28, 2013 Filed Jan 28, 2013 21:32 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
SaleCommon Stock, $0.10 par value | 20,350 | $36.19 | $736,466.50 |
DisclosureSEC source: 0001225208-13-002186 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000.018 F1 · shares: Shares sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.19 to $36.20, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F1 · price: Shares sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.19 to $36.20, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 28, 2013 Filed Jan 28, 2013 21:32 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionCommon Stock, $0.10 par value | 22,500 | $28.67 | $645,075.00 |
DisclosureSEC source: 0001225208-13-002186 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,350.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2013 Filed Jan 30, 2013 21:06 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $36.43 | $364,300.00 |
DisclosureSEC source: 0001225208-13-002478 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $36.14 to $36.56, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 25, 2013 Filed Jan 28, 2013 21:11 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $36.32 | $363,200.00 |
DisclosureSEC source: 0001225208-13-002174 · doc4.xml · nonDerivative · entry 3 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $35.86 to $36.60, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 24, 2013 Filed Jan 28, 2013 21:11 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 9,900 | $35.79 | $354,321.00 |
DisclosureSEC source: 0001225208-13-002174 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $35.57 to $35.95, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 24, 2013 Filed Jan 28, 2013 21:11 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 100 | $34.90 | $3,490.00 |
DisclosureSEC source: 0001225208-13-002174 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,181,118 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. Read SEC document |
| January 17, 2013 Filed Jan 18, 2013 21:40 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $34.33 | $343,300.00 |
DisclosureSEC source: 0001225208-13-001687 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,181,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $34.18 to $34.41, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 16, 2013 Filed Jan 18, 2013 21:40 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $34.33 | $343,300.00 |
DisclosureSEC source: 0001225208-13-001687 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,191,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $34.25 to $34.40, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 08, 2013 Filed Jan 9, 2013 21:15 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $33.58 | $335,800.00 |
DisclosureSEC source: 0001225208-13-001210 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $33.36 to $33.66, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2013 Filed Jan 9, 2013 21:15 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $33.40 | $334,000.00 |
DisclosureSEC source: 0001225208-13-001210 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,211,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $33.25 to $33.52, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2013 Filed Jan 7, 2013 21:25 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $33.26 | $332,600.00 |
DisclosureSEC source: 0001225208-13-000996 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,221,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $33.11 to $33.42, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2013 Filed Jan 7, 2013 21:25 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $32.98 | $329,800.00 |
DisclosureSEC source: 0001225208-13-000996 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.67 to $33.27, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2013 Filed Jan 7, 2013 21:25 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-000997 · doc4.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, $0.10 par value · 7,500 shares Expires 2015-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F3 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on January 3, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on January 3, 2011. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| January 03, 2013 Filed Jan 7, 2013 21:25 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Tax withholdingCommon Stock, $0.10 par value | 2,910 | $33.24 | $96,728.40 |
DisclosureSEC source: 0001225208-13-000997 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,850.018 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| January 03, 2013 Filed Jan 7, 2013 21:25 UTC |
Caforio GiovanniPres., US Pharmaceuticals
|
Exercise / conversionCommon Stock, $0.10 par value | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-000997 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,760.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2012 Filed Jan 2, 2013 21:10 UTC |
CORNELIUS JAMES MDirector
|
GrantCommon Stock, $0.10 par value | 767 | $32.59 | $24,996.53 |
DisclosureSEC source: 0001225208-13-000151 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241,218 F1 · shares: Shares awarded to Mr. Cornelius for service as the Non-Executive Chairman. Read SEC document |
| December 31, 2012 Filed Jan 3, 2013 21:26 UTC |
GROBSTEIN MICHAELDirector
|
GrantDeferred Share Units · Derivative | 310.09 | $32.45 | $10,062.42 |
DisclosureSEC source: 0001225208-13-000564 · doc4.xml · derivative · entry 1 GROBSTEIN MICHAEL · CIK 0001222342 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,691.83 Underlying: Common Stock, $0.10 par value · 310.09 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 31, 2012 Filed Jan 3, 2013 21:26 UTC |
Storch Gerald LDirector
|
GrantDeferred Share Units · Derivative | 885.98 | $32.45 | $28,750.05 |
DisclosureSEC source: 0001225208-13-000565 · doc4.xml · derivative · entry 1 Storch Gerald L · CIK 0001205004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,681.39 Underlying: Common Stock, $0.10 par value · 885.98 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 28, 2012 Filed Dec 28, 2012 22:59 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $32.09 | $320,900.00 |
DisclosureSEC source: 0001225208-12-026240 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,240,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $31.91 to $32.25, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 27, 2012 Filed Dec 28, 2012 22:59 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $32.02 | $320,200.00 |
DisclosureSEC source: 0001225208-12-026240 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $31.85 to $32.33, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2012 Filed Dec 21, 2012 22:56 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $32.48 | $324,800.00 |
DisclosureSEC source: 0001225208-12-025878 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.37 to $32.62, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 20, 2012 Filed Dec 21, 2012 22:56 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $32.52 | $325,200.00 |
DisclosureSEC source: 0001225208-12-025878 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.36 to $32.63, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 17, 2012 Filed Dec 18, 2012 21:15 UTC |
Bancroft Charles AEVP & Chief Financial Officer
|
Exercise / conversionOption (right to buy) · Derivative | 26,875 | $0.00 Strike: $23.14 | $0.00 |
DisclosureSEC source: 0001225208-12-025592 · doc4.xml · derivative · entry 5 Bancroft Charles A · CIK 0001480250 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 26,875 shares Expires 2013-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 4, 2003. Read SEC document |
| December 17, 2012 Filed Dec 18, 2012 21:15 UTC |
Bancroft Charles AEVP & Chief Financial Officer
|
Exercise / conversionOption (right to buy) · Derivative | 20,250 | $0.00 Strike: $28.11 | $0.00 |
DisclosureSEC source: 0001225208-12-025592 · doc4.xml · derivative · entry 4 Bancroft Charles A · CIK 0001480250 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 20,250 shares Expires 2014-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 2, 2004. Read SEC document |
| December 17, 2012 Filed Dec 18, 2012 21:15 UTC |
Bancroft Charles AEVP & Chief Financial Officer
|
SaleCommon Stock, $0.10 par value | 42,844 | $32.77 | $1,403,997.88 |
DisclosureSEC source: 0001225208-12-025592 · doc4.xml · nonDerivative · entry 3 Bancroft Charles A · CIK 0001480250 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,076.166 F1 · shares: A portion of these shares were sold to cover exercise price and taxes in accordance with broker's procedures for sell-to-cover transactions. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.76 to $32.79, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 17, 2012 Filed Dec 18, 2012 21:15 UTC |
Bancroft Charles AEVP & Chief Financial Officer
|
Exercise / conversionCommon Stock, $0.10 par value | 20,250 | $28.11 | $569,227.50 |
DisclosureSEC source: 0001225208-12-025592 · doc4.xml · nonDerivative · entry 2 Bancroft Charles A · CIK 0001480250 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,920.166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2012 Filed Dec 18, 2012 21:15 UTC |
Bancroft Charles AEVP & Chief Financial Officer
|
Exercise / conversionCommon Stock, $0.10 par value | 26,875 | $23.14 | $621,887.50 |
DisclosureSEC source: 0001225208-12-025592 · doc4.xml · nonDerivative · entry 1 Bancroft Charles A · CIK 0001480250 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,670.166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2012 Filed Dec 13, 2012 21:20 UTC |
CORNELIUS JAMES MDirector
|
Exercise / conversionExecutive Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0001225208-12-025236 · doc4.xml · derivative · entry 4 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,996 Underlying: Common Stock, $0.10 par value · 400,000 shares Expires 2018-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: As Mr. Cornelius had attained age 60, this stock option award vested 100% on the first anniversary of the grant date, which was March 4, 2009. Read SEC document |
| December 12, 2012 Filed Dec 13, 2012 21:20 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $33.31 | $333,100.00 |
DisclosureSEC source: 0001225208-12-025236 · doc4.xml · nonDerivative · entry 3 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $33.09 to $33.51, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2012 Filed Dec 13, 2012 21:20 UTC |
CORNELIUS JAMES MDirector
|
GrantCommon Stock, $0.10 par value | 400,000 | $22.14 | $8,856,000.00 |
DisclosureSEC source: 0001225208-12-025236 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290,451 Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 21:28 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
SaleCommon Stock, $0.10 par value | 62,903 | $33.00 | $2,075,799.00 |
DisclosureSEC source: 0001181431-12-064463 · rrd363264.xml · nonDerivative · entry 7 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By Ruth L. Sigal 2012 Irrevocable Trust Disclosed balance after: 37,412 F5 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.81 to $33.23, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 21:28 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
SaleCommon Stock, $0.10 par value | 62,903 | $33.00 | $2,075,799.00 |
DisclosureSEC source: 0001181431-12-064463 · rrd363264.xml · nonDerivative · entry 6 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By C. Elliott Sigal 2012 Irrevocable Trust Disclosed balance after: 37,412 F5 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.81 to $33.23, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 21:28 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
SaleCommon Stock, $0.10 par value | 31,451 | $33.00 | $1,037,883.00 |
DisclosureSEC source: 0001181431-12-064463 · rrd363264.xml · nonDerivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By Sigal Family Investments, LLC Disclosed balance after: 18,707 F5 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.81 to $33.23, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2012 Filed Dec 13, 2012 21:20 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $33.10 | $331,000.00 |
DisclosureSEC source: 0001225208-12-025236 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.82 to $33.21, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 04, 2012 Filed Dec 4, 2012 22:08 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $32.64 | $326,400.00 |
DisclosureSEC source: 0001225208-12-024462 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.43 to $32.80, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2012 Filed Dec 4, 2012 22:08 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $32.68 | $326,800.00 |
DisclosureSEC source: 0001225208-12-024462 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.42 to $32.83, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 28, 2012 Filed Nov 29, 2012 21:08 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $32.58 | $325,800.00 |
DisclosureSEC source: 0001225208-12-024016 · doc4.xml · nonDerivative · entry 2 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.24 to $32.76, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 27, 2012 Filed Nov 29, 2012 21:08 UTC |
CORNELIUS JAMES MDirector
|
SaleCommon Stock, $0.10 par value | 10,000 | $32.69 | $326,900.00 |
DisclosureSEC source: 0001225208-12-024016 · doc4.xml · nonDerivative · entry 1 CORNELIUS JAMES M · CIK 0001198959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930,451 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2012. F2 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $32.59 to $32.81, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 27, 2012 Filed Dec 13, 2012 21:28 UTC |
SIGAL ELLIOTDirector · EVP, CSO & President R&D
|
GiftCommon Stock, $0.10 par value | 100,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-12-064463 · rrd363264.xml · nonDerivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · Director · EVP, CSO & President R&D 10b5-1 filing: Not disclosed Ownership: Indirect · By Ruth L. Sigal 2012 Irrevocable Trust Disclosed balance after: 100,315 F3 · shares: On November 27, 2012, the reporting person's wife contributed her 40% interest in SFI to the Ruth L. Sigal 2012 Irrevocable Trust for the benefit of the reporting person and their children. F4 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purpose. F3 · ownership.nature: On November 27, 2012, the reporting person's wife contributed her 40% interest in SFI to the Ruth L. Sigal 2012 Irrevocable Trust for the benefit of the reporting person and their children. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.